Sep 13, 2021
Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp
Corporate
Jul 21, 2021
Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
Corporate
Jul 01, 2021
Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions
Corporate
Jun 16, 2021
Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics
Corporate
Jun 04, 2021
Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
Corporate
Jun 01, 2021
Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
Corporate
May 24, 2021
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
Corporate
May 20, 2021
Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business
Corporate
May 05, 2021
Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference
Corporate
May 03, 2021
Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp
Corporate
May 03, 2021
Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day
Corporate
Apr 27, 2021
Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021
Corporate
Apr 27, 2021
Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
Corporate
Mar 29, 2021
Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders
Corporate
Feb 18, 2021
Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives
Corporate